Abstract. The migration and concentration of lymphocytes at sites of antigenic challenge are an integral part of the expression of delayed cutaneous hypersensitivity, as well as of tumor and graft rejection. In this study, we have analyzed the migration of T lymphocytes from patients with malignancy. We used casein and concanavalin A (Con A)-stimulated mononuclear cell supernatants to stimulate T cell locomotion. Peripheral blood T lymphocytes from 30 patients with established malignancy, 10 patients with indolent malignancy or benign tumor, and 42 normal adult controls were tested. Data are expressed as a migration index (MI), which represents the difference in micrometers between the distance migrated in response to a stimulus and the distance migrated in response to media alone. We observed a marked depression in casein-stimulated T lymphocyte migration in patients with established malignancy (mean MI± 1 SD = 17.0±9 um) as compared with normal adult controls (mean MI±1 SD = 35.3±10 um). Similar results were observed with migration in response to Con A supernatants. T cells from patients with established malignancy had a mean MI of 5.8±4 Am to Con A supernatants as compared with 24.5±5 for controls. This depressed migration was apparent both in the distance that cells migrated and in the number of cells that migrated into the membrane. Of 10 patients with indolent malignancy or benign tumor, T 
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Received for publication 10 May 1983 and in revised form 15 December 1983. the mixture directly to the upper compartment of the chemotaxis chamber, the response of the normal T cells to casein was inhibited by an average of48%. We observed inhibition ofthis migration ofnormal cells when we added as little as 10% of patient cells to normal cells. When we mixed normal control T lymphocytes from different donors and added them directly to the upper compartment of the chemotaxis chamber, T lymphocyte migration in response to casein was not significantly altered. If T cells from patients with cancer were cultured overnight, the suppressive effect on lymphocyte locomotion was lost. Our results indicate that there is a population of T lymphocytes in patients with cancer that suppress normal T lymphocyte migration. This suppressor activity may partially explain the subversion of immunosurveillance in established neoplastic states, as well as the defective inflammatory reaction to intradermal injection of antigen observed in many patients with malignancy.
Introduction
Depressed cell-mediated immune responses have been well documented in patients with cancer, including patients with lymphoid as well as nonlymphoid tumors. Depressed lymphocyte proliferation in response to phytohemagglutinin (1) (2) (3) (4) , as well as depressed cutaneous hypersensitivity reactions (1, 2, 5-8) and prolonged skin allograft rejection (9, 10) have been observed in individuals with tumors. These observations indicate an impairment of the T lymphocyte effector arm of the immune response. The importance of the mobilization of mononuclear cells to a tumor site is indicated by studies that show that the prognosis is more favorable for patients with certain types of tumor when the tumor is accompanied by an extensive mononuclear (MN)' cell infiltration. In fact, the claim has been made that among patients with these tumors, those who show the most intense MN cell infiltration survive the longest (1 1).
Many groups have studied abnormalities of monocyte chemotaxis in patients with cancer (12-17). Recently, techniques have been developed to analyze lymphocyte migration in vitro (18) (19) (20) (21) (22) (23) . In this study, we show that T lymphocyte migration is depressed in patients with established malignancy, and that it can be attributed to the presence of a suppressor cell population.
Methods
Patients and controls. Heparinized peripheral venous blood samples were obtained from 30 patients with pathologic diagnoses of malignant neoplastic disease; these included 6 with adenocarcinoma of the breast, 5 with lung cancer (2 oat cell and 3 adenocarcinoma), 3 with adenocarcinoma of the colon, 3 with transitional cell bladder carcinoma, 2 with squamous cell cervical cancer, 2 with adenocarcinoma ofthe prostate, 2 with lymphoma (1 diffuse histiocytic and 1 nodular sclerosing Hodgkin's disease), 1 with pleomorpholiposarcoma, I with multiple myeloma, 1 with malignant melanoma, I with carcinoma of the ovary, 1 with endometrial cancer, 1 with a mucoepidermoid parotid gland tumor, and 1 patient with widespread malignancy whose primary was unknown; ages of these patients ranged from 18 (24) , and was >95% E-rosetting lymphocytes. Patient cell preparations with 5% or more peroxidase-staining MN cells were not used in this study. In some cases MN cells were passed through a glass wool column before incubation with SRBC (21) . Isolated T lymphocytes were washed and resuspended to 2 X 106 cells/ ml in the media appropriate for each assay.
T lymphocyte locomotion assay. T lymphocyte locomotion assays were performed in blind-well Boyden chambers (Nuclepore Corp., Pleasanton, CA) using a modification of the leading front technique developed for neutrophils by Zigmond and Hirsch (25) . The assay performed here used an 8-gm-pore-size cellulose nitrate membrane (Sartorius Filters, Inc., Hayward, CA) to separate the upper and lower compartments. Casein or supernatant from Con A-stimulated mononuclear cells was added to the lower compartment of the chemotaxis chamber to stimulate lymphocyte migration. T lymphocytes (4 X lO cells or 2 X lO cells) were added to the upper compartment and allowed to migrate into the membrane for 3 h at 370C, after which the membrane was fixed in formaldehyde, stained with hematoxylin, and cleared with isopropyl alcohol and xylene, as previously described (20) . Cell migration was measured by the leading front method, which used the microscope micrometer to measure the distance that the leading three cells had traveled into the membrane. Morphologically, these cells were lymphocytes, as determined by light microscopy. Data were expressed as mean migration in micrometers ±1 SD or as a migration index (MI), which represents the difference between the lymphocyte response to a locomotor stimulus and that observed with media alone. In some cases, the number ofcells responding to the stimulus was determined by counting those cells per 400X field that migrated beyond 20 grm into the membrane. In each case, results represent the mean number of cells per 400X field (five fields were counted) on each oftwo duplicate membranes.
Preparation ofagents used to stimulate lymphocyte migration. Stock casein (Fisher Scientific Co., Allied Corp., Pittsburgh, PA) preparations were prepared by adding casein (2 mg/ml) to MEM and agitating periodically for 2 h at 370C. Casein was then used at a final concentration of 0.4 mg/ml in the lower compartment of the chemotaxis chamber to stimulate locomotion.
Lymphocyte chemotactic factor from Con A-stimulated MN cells was prepared as previously described (22) . Briefly, 5 X 106 peripheral blood MN cells in MEM that contained 1% human AB serum were cultured for 24 h with 0.5 sg/ml of Con A (Sigma Chemical Co., St. Louis, MO). Supernatants that contained T lymphocyte chemotactic factor were removed and mixed with 25 mM a-methyl-D-mannoside to block the binding of any residual Con A to lymphocytes in the chemotaxis assay system. Control media for the factor consisted ofculture media that contained 0.5 jg/ml of Con A plus 25 mM a-methyl-D> mannoside. The addition of Con A plus a-methyl-D-mannoside did not alter random lymphocyte migration.
Lymphocyte culturing procedure. In some cases, T lymphocytes were resuspended in MEM supplemented with 1%, 560C, heat-inactivated human AB serum, 2 mM l-glutamine, and 0.1% gentamycin. The suspensions were incubated at 370C for 24 Am). This significant difference was also apparent when the absolute migration ofT cells from patients or controls in response to casein was compared (P < 0.001). Since the mean age of patients with malignancy was 56±18 with a range from 18 to 83 yr whereas controls averaged 32±15 with a range of 19 to 64 yr, we analyzed our data to determine if a correlation between age and T cell migration existed in either group. We found no correlation between age and T cell responsiveness to casein in any group. We obtained the data shown in Fig. 1 with T cells prepared directly from MN cells by E-rosette formation with SRBC. We obtained similar results with patient MN cells depleted of adherent cells by passage through glass wool before preparation of E-rosettes.
Because previous studies have shown that casein enhances T lymphocyte random migration and that it is therefore chemokinetic (21), we conducted additional studies (Fig. 2) to determine ifthe migration of T lymphocytes in response to Con A-stimulated MN cell supernatants containing lymphocyte chemoattractant activity (22) was abnormal. We tested T lymphocytes from six patients with established malignancy for locomotor activity in response to Con A-stimulated MN cell supernatant and we compared their activity to that of normal controls. As shown in Fig. 2 , the response of T cells from patients with established malignancy to Con A supernatants was suppressed (MI± 1 SD = 5.8±4 Mm) as compared with normal adult controls (mean MI±1 SD = 24.5±5 Mm). Random locomotion was similar in both patients and controls (mean ± 1 SD = 28±10 and 26±8 Am, respectively).
Since the leading front technique measures only the migration of the leading three cells, we performed experiments to determine if suppressed T lymphocyte migration in patients with cancer is also reflected in the number of cells that respond. 10 patients with benign tumor or indolent malignancy to determine ifdepressed T lymphocyte migration was associated with these conditions. Fig. 4 compares lymphocyte migration in response to casein in each of these 10 patients to migration of T cells from the original 30 patients with established malignancies. The 10 patients with benign neoplasm or indolent malignancy showed an MI±1 SD of40.3+24, which is comparable to the MI of normal controls (mean MI± 1 SD = 35.3±10) and much greater than the MI of patients with established malignancy (mean ±1 SD = 17.0±9). Statistical analysis by t test showed that T cell migration in response to casein as measured by MI or absolute distance was significantly suppressed (P < 0.001) in patients with established tumor as compared with both normal controls and patients with benign tumor. Furthermore, T cell migration in response to casein did not differ significantly (P = 0.213) among patients with benign tumor and normal controls, nor did random lymphocyte migration differ significantly (P = 0.7) among patients with established malignancy (mean ±1 SD = 34.8+±13 Am) and patients with benign tumor or indolent malignancy (mean ±1 SD = 37±9 im).
Suppression of normal T lymphocyte migration by T cells from patients with cancer. Fig. 5 shows the results of two representative experiments in which equal concentrations of normal and patient T lymphocytes were added directly to the upper compartment of the chemotaxis chamber. Absolute distance, plotted on the left, revealed no significant difference in random migration when either 4 X 105 or 2 X 105 control cells were used in the migration assay. Similarly, we saw no significant difference in random migration of patient cells at these two cell concentrations. When 2 X l10 patient cells and 2 X l10 control cells were mixed, random migration was equivalent to control or to patient values. As shown on the right of Fig. 5 , halving the cell concentration did not affect the response to casein with either control or patient T lymphocyte suspensions. When we added 2 X l10 patient cells to 2 X l10 control cells, we saw a marked reduction in the MI of control cells in response to casein, but random migration was unaffected. The suppression of normal T cell migration by patient T cells was demonstrable both by the leading front assay and by counting the cells that migrated beyond 20 Am into the membrane (Fig. 6) . Furthermore, the addition of 10-50% normal cells from one normal donor to normal cells from another donor had a negligible effect on the leading front assay, and enhanced the number of cells that migrated beyond 20 in. The addition of as few as 10% T cells from a patient with established tumor markedly suppressed normal T cell migration as measured by both methods of analysis. The data shown in Fig. 6 are representative results from two patients with a T cell migration of <50% of the mean of normal controls as measured by the leading front assay.
The data in Fig. 7 show results of mixing experiments obtained with cells from 11 T cells to casein was inhibited by an average of 47.5%. We noted no association between the degree of suppressive activity and previous chemotherapy, radiation treatment, or the degree of metastatic disease. In experiments with three different subjects where cells were cultured for 24 h at 370C before being added to normal T cells in the migration assay, the suppressive effect by cancer patient cells was lost. These results indicated that there was a population of T lymphocytes in patients with established malignancy that suppressed normal T lymphocyte migration and that the suppressor activity was lost after 24 (23) . Alternatively, suppressed migration may be due to tumor-derived factors such as tumor antigen-antibody complexes bound to the cell surface of T lymphocytes (36) . Such complexes could be shed after overnight incubation, releasing the T cell population from the suppressed locomotor responses shown before culture. It is also possible that surface-bound tumor antigen-antibody complexes not only suppress T lymphocyte locomotion but that they induce a population of suppressor cells that can regulate the migration of lymphocytes whose surfaces are not bound to tumor antigenantibody complexes. Parrott and co-workers have described a heterogeneity oflocomotion to casein in human peripheral blood T lymphocyte subpopulations (19 culture for 24 h could also explain the loss of suppression in the lymphocyte migration assay after overnight culture of cancer patient T cells. Gupta and Tan have speculated that with a large population of T-y in the peripheral blood, as is found in patients with Hodgkin's disease (38, 39) , the T lymphocyte response to casein may be diminished. These authors have proposed that the maldistribution of nonresponsive subpopulations of T cells is responsible for the depressed locomotor behavior of the peripheral blood T lymphocytes. If such were the case in the patients with cancer studied here, a mixture of normal peripheral blood T cells with T cells from patients with cancer should still show normal migration, since a large enough population of Tjs cells would be present and their migration measurable. As we have shown in our system, normal migration was not observed when normal and cancer patient lymphocytes were mixed, implying that decreased migration is the result of an active suppression and not simply because of the absence of responding cells.
In summary, our data suggest that suppressed T lymphocyte migration is a generalized phenomenon in patients with established neoplastic disease. This suppressed migration may be attributable in part to the action ofa suppressor cell population. Moreover, the observed suppressor activity may partially explain the decreased cellular immunity observed in malignant states.
